FK 866

Pricing Availability   Qty
说明: Potent and non-competitive NAMPT inhibitor; induces apoptosis and autophagy
化学名: (2E)-N-[4-(1-Benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide
纯度: ≥98% (HPLC)
说明书
引用文献
评论 (1)
文献 (1)

生物活性 for FK 866

FK 866 is a non-competitive and high-affinity inhibitor of NAMPT (nicotinamide phosphoribosyltransferase, PBEF1) (Ki = 0.3 nM); inhibits NAD biosynthesis. Induces delayed cell death by apoptosis in HepG2 human liver carcinoma cells (IC50 ~1 nM). Induces apoptosis in four different neuroblastoma cell lines; also induces autophagy in SH-SY5Y cells. Potentiates the cytotoxic effects induced by Etoposide (Cat. No. 1226) and Cisplatin (Cat. No. 2251).

技术数据 for FK 866

分子量 391.51
公式 C24H29N3O2
储存 Store at -20°C
纯度 ≥98% (HPLC)
CAS Number 658084-64-1
PubChem ID 6914657
InChI Key KPBNHDGDUADAGP-VAWYXSNFSA-N
Smiles C(=O)(N1CCC(CCCCNC(/C=C/C=2C=CC=NC2)=O)CC1)C3=CC=CC=C3

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for FK 866

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 39.15 100
ethanol 39.15 100

制备储备液 for FK 866

以下数据基于产品分子量 391.51。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 2.55 mL 12.77 mL 25.54 mL
5 mM 0.51 mL 2.55 mL 5.11 mL
10 mM 0.26 mL 1.28 mL 2.55 mL
50 mM 0.05 mL 0.26 mL 0.51 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

参考文献 for FK 866

参考文献是支持产品生物活性的出版物。

Hasmann et al (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63 7436 PMID: 14612543

Travelli et al (2011) Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etop. or cisp. in neuroblastoma cells. J.Pharmacol.Exp.Ther. 338 829 PMID: 21685314

Galli et al (2008) Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage. Chem.Med.Chem. 3 771 PMID: 18247435


If you know of a relevant reference for FK 866, please let us know.

按产品操作查看相关产品

查看全部 NAMPT Inhibitors

关键词: FK 866, FK 866 supplier, FK866, Nicotinamide, phosphoribosyltransferase, NMPRTase, inhibitors, inhibits, autophagy, apoptosis, NAD, NAMPT, potent, non-competitive, Apoptosis, Inducers, Autophagy, 8072, Tocris Bioscience

篇 FK 866 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 FK 866 的引用文献。 您是否知道使用了 Tocris FK 866 的优秀论文? 请告知我们.

FK 866 的评论

平均评分: 5 (Based on 1 Review.)

5 星
100%
4 星
0%
3 星
0%
2 星
0%
1 星
0%

Have you used FK 866?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


FK 866.
By Anonymous on 12/19/2023
分析类型: In Vitro
种属: Human
细胞系/组织: RBE and HepG2

I used FK 866 in 10–50 nM concentrations for 24-72 hours and noted significant differences in cellular NAD level and cell growth.

Treat this drug for 72 hours for best results.

review image

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Cancer Metabolism Poster

Cancer Metabolism Poster

This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.